Comparison of the Efficacy and Safety of Insulin Detemir Administered Once Daily According to Two Titration Algorithms (3-0-3 and 2-4-6-8) in Patients with Type 2 Diabetes Mellitus
- Abstract
- BACKGROUND: This study was conducted to compare glycaemic control with insulin detemir administered according to two titration algorithms (3-0-3 and 2-4-6-8) after 20 weeks of treatment in subjects with type 2 diabetes mellitus inadequately controlled on metformin. METHODS: This was a 20-week, randomised, multicentre, open-labelled, treat-to-target trial. Forty-six patients were randomised in a 1:1 manner to either the 3-0-3 (G3, n=23) or 2-4-6-8 (G2, n=23) algorithm. The primary endpoint was change of haemoglobin A1c (HbA1c), and the secondary safety endpoint included hypoglycaemic events. RESULTS: After 20 weeks, HbA1c decreased similarly in the G3 and G2 groups, with a mean change of -0.9% from baseline. The mean change in fasting plasma glucose was numerically similar in both groups. The hypoglycaemia event rate per 100-patient-years of exposure (r) in the G2 group (r=1,427) was higher than that in the G3 group (r=807). CONCLUSION: Both treatment groups had numerically similar HbA1c reductions. A trend towards fewer hypoglycaemia episodes after dose stabilisation was seen with the simpler G3. Clinically, this may be an important observation, as a simpler titration algorithm may support self-management and maintenance of insulin therapy.
- All Author(s)
- H. M. Yu
; K. S. Park
; J. H. Hong
; K. Y. Park
; J. M. Lee
; B. J. Ku
; Y. J. Kim
; T. K. Oh
- Issued Date
- 2020
- Type
- Article
- Keyword
- Hyperglycemia; Insulin; Algorithms; Diabetes mellitus, type 2
- Publisher
- 대한내분비학회
- ISSN
- 2093-596X
- Citation Title
- Endocrinology and Metabolism
- Citation Volume
- 35
- Citation Number
- 1
- Citation Start Page
- 142
- Citation End Page
- 148
- Language(ISO)
- eng
- DOI
- 10.3803/EnM.2020.35.1.142
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/2327
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.